EFDID: 348268EFD: View Filing

Issuer: Kintara Therapeutics, Inc. (0001498382) - D

Accession: 0000905718-20-000907 (XMLRaw Data) (EDGAREDGAR Files) (Form DForm D)

EDGAR: Issuer Information
  • CIK:
    0001498382
  • Entity Name:
    Kintara Therapeutics, Inc.
  • Entity Type:
    Corporation
  • Jurisdiction:
    NEVADA
  • Year of Inc:
    Over 5 years ago
  • Address:
    12707 HIGH BLUFF DR., SUITE 200
    SAN DIEGO, CA 92130
  • Persons:
    Related Persons 9
    Saiid Zarrabian
    Executive Officer, Director
    Dennis Brown
    Executive Officer
    Scott Praill
    Executive Officer
    John Liatos
    Executive Officer, Director
    Robert Hoffman
    Director
    Robert Toth
    Director
    Laura Johnson
    Director
    Keith Murphy
    Director
    Steven Rychnovsky
    Executive Officer
EDGAR: Offering Information
  • Accession Date:
    08/28/2020
  • First Sale Date:
    08/19/2020
  • Offering Amount:
    $30,000,000
  • Amount Sold:
    $21,772,000
  • Amount Remaining:
    $8,228,000
  • Exemptions:
    Rule 506
  • Security Type(s):
    Equity, Series C Convertible Preferred Stock
EFD: Current State Notices
View Notices

Notices found in EFD

Filed:AL, CA, MA, MD, NC, NH, NJ, OH, PA, UT, VA, WI
Inactive:AK, CO, GA, LA, MT, ND, PR, TN, WA
EDGAR: Sales Compensation Recipient Information
RecipientCRDBroker DealerBD CRDStates
Aegis Capital Corp. 15007 None None All States
EDGAR: Signatures
IssuerSignatureSigner NameTitleSignatureDate
Kintara Therapeutics, Inc./s/ Scott PraillScott PraillCFO2020-08-28